Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-08-10
Based on 414 first isolates · MED-B · Cystitis (lower UTI) · 2024-08-11 → 2025-08-10
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 85 % (81 %–88 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (4 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
86 %
n = 29
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
85 %
90 %
n = 29
ciprofloxacin CIP
trend · Escherichia coli
78 %
79 %
n = 29
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
78 %
79 %
n = 29
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
83 %
n = 29
ceftriaxone CRO
trend · Escherichia coli
77 %
86 %
n = 29
73 %
86 %
n = 29
trimethoprim TMP
trend · Escherichia coli lower UTI only
70 %
83 %
n = 29
49 %
52 %
n = 29
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
7 %
n = 29
4 %
0 %
n = 29
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
3 %
n = 29

Most likely organisms for this profile

Escherichia coli
57 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
10 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
4 %
Citrobacter freundii
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.